You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company is also participating in a study, being conducted at Hannover Medical School, investigating the genetics of susceptibility to COVID-19.
The company withdrew its 2020 revenue guidance and said it expects to report revenues of more than $63 million in the quarter ended March 31.
The company announced an agreement with Piper Sandler & Co. to act as agent, creating an at-the-market equity program for up to $25 million in shares of its common stock.
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
The company expects that proceeds from this transaction, combined with another direct offering earlier this week and its current cash reserve, can support operations through the end of this year.
The firm has entered into a securities purchase agreement for the issuance and sale of 23 million shares of its common stock at $0.40 per share.
The offering is for 470,000 shares priced at-the-market which the firm will use for infectious disease test supplies and assay development.
The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.